Drug Profile


Alternative Names: LF 160687; LF16-0687MS; XY-2405

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Fournier Pharma
  • Developer Fournier Pharma; London School of Hygiene & Tropical Medicine
  • Class Analgesics; Anti-inflammatories; Quinolines; Small molecules
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Brain injuries

Most Recent Events

  • 15 Mar 2007 Xytis initiates enrolment in the BRAIN trial for traumatic brain injury
  • 11 Jan 2007 Phase-II clinical trials in Head injuries in South Africa (SC)
  • 11 Jan 2007 Phase-II clinical trials in Head injuries in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top